The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the first-line chemotherapy for patients with advanced gastric cancer.
Inkeun Park
No relevant relationships to disclose
Min-Hee Ryu
No relevant relationships to disclose
Baek-Yeol Ryoo
No relevant relationships to disclose
Myoung Joo Kang
No relevant relationships to disclose
Changsuk Lee
No relevant relationships to disclose
Young Soo Park
No relevant relationships to disclose
Yoon-Koo Kang
Honoraria - Novartis
Research Funding - Novartis